. 2017 Mar 2;56(10):1245–1253. doi: 10.1007/s40262-017-0516-6

Table 2.

Summary of the studies included in the population PK analysis

Study	Phase	n ^a	No. of CdA samples^b		No. of CAde samples^b		Treatment: administration and dose (cumulative)
Study	Phase	n ^a	Plasma	Urine	Plasma	Urine	Treatment: administration and dose (cumulative)
25803	I	16	404	166	189	89	CdA: 3 mg IV infusion/10 mg single oral doses
26127	I	16	416	–	–	–	CdA: 10 mg single oral doses
26486	I	16	419	–	–	–	CdA: 1.75 mg/kg orally over 8 weeks + IFNβ-1a
25643	III	125	470	–	466	–	CdA: 3.5 or 5.25 mg/kg orally over 2 years

PK pharmacokinetic, CdA cladribine, CAde 2-chloroadenine, IV intravenous, IFN interferon, RRMS relapsing-remitting multiple sclerosis

^aNumber of CdA-treated RRMS patients included in the population PK analysis

^bTotal number of samples available for the population PK analysis